A Phase I Study of Intravenous Fenretinide (4-HPR) for Patients with Malignant Solid Tumors

BACKGROUND: Fenretinide is a synthetic retinoid that can induce cytotoxicity by several mechanisms. Achieving effective systemic exposure with oral formulations has been challenging. An intravenous lipid emulsion fenretinide formulation was developed to overcome this barrier. We conducted a study to...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Cancer Chemother Pharmacol
Autors principals: Thomas, Jacob S., El-Khoueiry, Anthony B., Maurer, Barry J., Groshen, Susan, Pinski, Jacek K., Cobos, Everardo, Gandara, David R., Lenz, Heinz J., Kang, Min H, Reynolds, C. Patrick, Newman, Edward M.
Format: Artigo
Idioma:Inglês
Publicat: 2021
Matèries:
Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC8058950/
https://ncbi.nlm.nih.gov/pubmed/33423090
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s00280-020-04224-8
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars